Announcement on Voluntary Disclosure Regarding the Company's Earnings Call
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Voluntary Disclosure Regarding the Company's Earnings Call
Filed with SSE · · 1 page · Chinese
Release
Earlier from BeOne Medicines
- Announcement on Nomination of the Board of Directors and Changes in Members of the Corporate Governance Committee
- Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2025
- Announcement on Voluntary Disclosure of the Change of the Company's NASDAQ Stock Code
- Announcement on Voluntary Disclosure of the Incorporation of Commercial Products for Multiple Indications into the New Catalogue of Drugs for Basic National Medical Insurance
- Announcement on Proposed Change of Company's English Name
Later from BeOne Medicines
- Indicative Announcement on Equity Change of Shareholders with Over 5% Shares
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
- Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1%
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines